Skip to main content
Springer Nature Link
Log in

Inhibitors of Advanced Glycation End Product (AGE) Formation and Accumulation

  • Chapter
  • First Online:
Reactive Oxygen Species

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 264))

Abstract

A range of chemically different compounds are known to inhibit the formation and accumulation of advanced glycation end products (AGEs) or disrupt associated signalling pathways. There is evidence that some of these agents can provide end-organ protection in chronic diseases including diabetes. Whilst this group of therapeutics are structurally and functionally different and have a range of mechanisms of action, they ultimately reduce the deleterious actions and the tissue burden of advanced glycation end products. To date it remains unclear if this is due to the reduction in tissue AGE levels per se or the modulation of downstream signal pathways. Some of these agents either stimulate antioxidant defence or reduce the formation of reactive oxygen species (ROS), modify lipid profiles and inhibit inflammation. A number of existing treatments for glucose lowering, hypertension and hyperlipidaemia are also known to reduce AGE formation as a by-product of their action. Targeted AGE formation inhibitors or AGE cross-link breakers have been developed and have shown beneficial effects in animal models of diabetic complications as well as other chronic conditions. However, only a few of these agents have progressed to clinical development. The failure of clinical translation highlights the importance of further investigation of the advanced glycation pathway, the diverse actions of agents which interfere with AGE formation, cross-linking or AGE receptor activation and their effect on the development and progression of chronic diseases including diabetic complications.

Graphical Abstract

Advanced glycation end products (AGEs) are (1) proteins or lipids that become glycated as a result of exposure to sugars or (2) non-proteinaceous oxidised lipids. They are implicated in ageing and the development, or worsening, of many degenerative diseases, such as diabetes, atherosclerosis, chronic kidney and Alzheimer’s disease. Several antihypertensive and antidiabetic agents and statins also indirectly lower AGEs. Direct AGE inhibitors currently investigated include pyridoxamine and epalrestat, the inhibition of the formation of reactive dicarbonyls such as methylglyoxal as an important precursor of AGEs via increased activation of the detoxifying enzyme Glo-1 and inhibitors of NOX-derived ROS to reduce the AGE/RAGE signalling.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Alhamdani MS, Al-Azzawie HF, Abbas FK (2007) Decreased formation of advanced glycation end-products in peritoneal fluid by carnosine and related peptides. Perit Dial Int 27(1):86–89

    CAS  PubMed  Google Scholar 

  • Alikhani Z et al (2005) Advanced glycation end products enhance expression of pro-apoptotic genes and stimulate fibroblast apoptosis through cytoplasmic and mitochondrial pathways. J Biol Chem 280(13):12087–12095

    CAS  PubMed  Google Scholar 

  • Babaei-Jadidi R et al (2003) Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52(8):2110–2120

    CAS  PubMed  Google Scholar 

  • Barnes PJ, Larin M (1997) Mechanisms of disease – nuclear factor-kappa-B – a pivotal transcription factor in chronic inflammatory diseases [review]. N Engl J Med 336(15):1066–1071

    CAS  PubMed  Google Scholar 

  • Baynes JW, Thorpe SR (1999) Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48(1):1–9

    CAS  PubMed  Google Scholar 

  • Beisswenger PJ et al (1995) Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 44(7):824–829

    CAS  PubMed  Google Scholar 

  • Beisswenger PJ et al (1999) Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 48(1):198–202

    CAS  PubMed  Google Scholar 

  • Berrone E et al (2006) Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem 281(14):9307–9313

    CAS  PubMed  Google Scholar 

  • Bierhaus A et al (2001) Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 50(12):2792–2808

    CAS  PubMed  Google Scholar 

  • Bierhaus A et al (2005a) Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83(11):876–886

    CAS  PubMed  Google Scholar 

  • Bierhaus A et al (2005b) Advanced glycation end product receptor-mediated cellular dysfunction. Ann N Y Acad Sci 1043:676–680

    CAS  PubMed  Google Scholar 

  • Bohlender J et al (2005) Advanced glycation end products: a possible link to angiotensin in an animal model. Ann N Y Acad Sci 1043:681–684

    CAS  PubMed  Google Scholar 

  • Booth AA et al (1997) In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-amadori glycation pathways. J Biol Chem 272(9):5430–5437

    CAS  PubMed  Google Scholar 

  • Brownlee M et al (1986) Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232:1629–1632

    CAS  PubMed  Google Scholar 

  • Bucciarelli LG et al (2002) RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106(22):2827–2835

    CAS  PubMed  Google Scholar 

  • Busch M et al (2008) Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension. Nephron Clin Pract 108(4):c291–c297

    CAS  PubMed  Google Scholar 

  • Candido R et al (2004) Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 109(12):1536–1542

    CAS  PubMed  Google Scholar 

  • Cao Z et al (2001) Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. Clin Sci (Colch) 100(6):591–599

    CAS  Google Scholar 

  • Chalmers J, Cooper ME (2008) UKPDS and the legacy effect. N Engl J Med 359(15):1618–1620

    CAS  PubMed  Google Scholar 

  • Cherney DZI et al (2017) Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5(8):610–621

    CAS  PubMed  Google Scholar 

  • Chetyrkin SV et al (2008) Pyridoxamine protects proteins from functional damage by 3-deoxyglucosone: mechanism of action of pyridoxamine. Biochemistry 47(3):997–1006

    CAS  PubMed  Google Scholar 

  • Cooper ME et al (2000) The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. Diabetologia 43(5):660–664

    CAS  PubMed  Google Scholar 

  • Coughlan MT, Forbes JM (2011) Temporal increases in urinary carboxymethyllysine correlate with albuminuria development in diabetes. Am J Nephrol 34(1):9–17

    CAS  PubMed  Google Scholar 

  • Coughlan MT et al (2007) Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? Endocrinology 148(2):886–895

    CAS  PubMed  Google Scholar 

  • Coughlan MT et al (2009) RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 20(4):742–752

    CAS  PubMed  PubMed Central  Google Scholar 

  • Davis BJ et al (2004) Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. Diabetologia 47(1):89–97

    CAS  PubMed  Google Scholar 

  • De Vriese AS et al (2001) Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. J Am Soc Nephrol 12(8):1734–1741

    PubMed  Google Scholar 

  • Degenhardt TP et al (2002) Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61(3):939–950

    CAS  PubMed  Google Scholar 

  • Dragomir E et al (2004) Aspirin rectifies calcium homeostasis, decreases reactive oxygen species, and increases NO production in high glucose-exposed human endothelial cells. J Diabetes Complications 18(5):289–299

    PubMed  Google Scholar 

  • Dragomir E et al (2006) Aspirin and PPAR-alpha activators inhibit monocyte chemoattractant protein-1 expression induced by high glucose concentration in human endothelial cells. Vascul Pharmacol 44(6):440–449

    CAS  PubMed  Google Scholar 

  • Du X, Edelstein D, Brownlee M (2008) Oral benfotiamine plus alpha-lipoic acid normalises complication-causing pathways in type 1 diabetes. Diabetologia 51(10):1930–1932

    CAS  PubMed  Google Scholar 

  • Endo N et al (2007) Vitamin B6 suppresses apoptosis of NM-1 bovine endothelial cells induced by homocysteine and copper. Biochim Biophys Acta 1770(4):571–577

    CAS  PubMed  Google Scholar 

  • Esteghamati A et al (2013) Effects of metformin on markers of oxidative stress and antioxidant reserve in patients with newly diagnosed type 2 diabetes: a randomized clinical trial. Clin Nutr 32(2):179–185

    CAS  PubMed  Google Scholar 

  • Fan Q et al (2004) Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/ta mice. Nephrol Dial Transplant 19(12):3012–3020

    CAS  PubMed  Google Scholar 

  • Febbraio M, Hajjar DP, Silverstein RL (2001) CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 108(6):785–791

    CAS  PubMed  PubMed Central  Google Scholar 

  • Feng B et al (2011) Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products. Biochim Biophys Acta 1812(9):1130–1137

    CAS  PubMed  PubMed Central  Google Scholar 

  • Figarola JL et al (2003) LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats. Diabetologia 46(8):1140–1152

    CAS  PubMed  Google Scholar 

  • Figarola JL et al (2008) LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat. Diabetologia 51(5):882–891

    CAS  PubMed  Google Scholar 

  • Forbes JM, Cooper ME (2013) Mechanisms of diabetic complications. Physiol Rev 93(1):137–188

    CAS  PubMed  Google Scholar 

  • Forbes JM et al (2003) The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 17(12):1762–1764

    CAS  PubMed  Google Scholar 

  • Forbes JM et al (2004) The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. Kidney Int Suppl 92:S105–S107

    CAS  Google Scholar 

  • Forbes JM et al (2005) Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 16(8):2363–2372

    CAS  PubMed  Google Scholar 

  • Forbes JM, Coughlan MT, Cooper ME (2008) Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57(6):1446–1454

    CAS  PubMed  Google Scholar 

  • Gao ZQ et al (2008) RAGE upregulation and nuclear factor-kappaB activation associated with ageing rat cardiomyocyte dysfunction. Gen Physiol Biophys 27(3):152–158

    PubMed  Google Scholar 

  • Genuth S et al (2005) Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 54(11):3103–3111

    CAS  PubMed  PubMed Central  Google Scholar 

  • Geoffrion M et al (2014) Differential effects of glyoxalase 1 overexpression on diabetic atherosclerosis and renal dysfunction in streptozotocin-treated, apolipoprotein E-deficient mice. Physiol Rep 2(6)

    Google Scholar 

  • Giunti S et al (2008) Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells. Diabetologia 51(1):198–207

    CAS  PubMed  Google Scholar 

  • Goldin A et al (2006) Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114(6):597–605

    CAS  PubMed  Google Scholar 

  • Gray SP, Jandeleit-Dahm KA (2015) The role of NADPH oxidase in vascular disease – hypertension, atherosclerosis & stroke. Curr Pharm Des 21(41):5933–5944

    CAS  PubMed  Google Scholar 

  • Gray SP et al (2013) NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation 127(18):1888–1902

    CAS  PubMed  Google Scholar 

  • Gray SP et al (2017) Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease. Diabetologia 60(5):927–937

    CAS  PubMed  Google Scholar 

  • Gu L et al (2006) Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant 21(2):299–313

    CAS  PubMed  Google Scholar 

  • Hamada Y et al (2000) Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care 23(10):1539–1544

    CAS  PubMed  Google Scholar 

  • Hammes HP et al (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9(3):294–299

    CAS  PubMed  Google Scholar 

  • Hanssen NM et al (2014a) Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype. Eur Heart J 35(17):1137–1146

    CAS  PubMed  Google Scholar 

  • Hanssen NM et al (2014b) Glyoxalase 1 overexpression does not affect atherosclerotic lesion size and severity in ApoE−/− mice with or without diabetes. Cardiovasc Res 104(1):160–170

    CAS  PubMed  Google Scholar 

  • Harcourt BE et al (2011) Targeted reduction of advanced glycation improves renal function in obesity. Kidney Int 80(2):190–198

    CAS  PubMed  Google Scholar 

  • Hartog JW et al (2005) Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease. Ann N Y Acad Sci 1043:299–307

    CAS  PubMed  Google Scholar 

  • Hill C et al (2000) The renal expression of transforming growth factor-beta isoforms and their receptors in acute and chronic experimental diabetes in rats. Endocrinology 141(3):1196–1208

    CAS  PubMed  Google Scholar 

  • Hipkiss AR, Chana H (1998) Carnosine protects proteins against methylglyoxal-mediated modifications. Biochem Biophys Res Commun 248(1):28–32

    CAS  PubMed  Google Scholar 

  • Hipkiss AR et al (1998) Pluripotent protective effects of carnosine, a naturally occurring dipeptide. Ann N Y Acad Sci 854:37–53

    CAS  PubMed  Google Scholar 

  • Horiuchi S et al (1996) Advanced glycation end products and their recognition by macrophage and macrophage-derived cells. Diabetes 45(Suppl 3):S73–S76

    CAS  PubMed  Google Scholar 

  • Horiuchi S et al (2005) Pathological roles of advanced glycation end product receptors SR-A and CD36. Ann N Y Acad Sci 1043:671–675

    CAS  PubMed  Google Scholar 

  • Humpert PM et al (2007) Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 6:9

    PubMed  PubMed Central  Google Scholar 

  • Iacobini C et al (2005) Development of age-dependent glomerular lesions in galectin-3/AGE-receptor-3 knockout mice. Am J Physiol Renal Physiol 289(3):F611–F621

    CAS  PubMed  Google Scholar 

  • Inagi R et al (2006) A severe diabetic nephropathy model with early development of nodule-like lesions induced by megsin overexpression in RAGE/iNOS transgenic mice. Diabetes 55(2):356–366

    CAS  PubMed  Google Scholar 

  • Inoguchi T et al (1992) Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci U S A 89(22):11059–11063

    CAS  PubMed  PubMed Central  Google Scholar 

  • Isoda K et al (2006) Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol 26(3):611–617

    CAS  PubMed  Google Scholar 

  • Ito Y et al (1998) Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 53(4):853–861

    CAS  PubMed  Google Scholar 

  • Jain SK, Lim G (2001) Pyridoxine and pyridoxamine inhibits superoxide radicals and prevents lipid peroxidation, protein glycosylation, and (Na+ + K+)-ATPase activity reduction in high glucose-treated human erythrocytes. Free Radic Biol Med 30(3):232–237

    CAS  PubMed  Google Scholar 

  • Janssen B et al (2005) Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1. Diabetes 54(8):2320–2327

    CAS  PubMed  Google Scholar 

  • Jha JC et al (2014) Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy. J Am Soc Nephrol 25(6):1237–1254

    CAS  PubMed  PubMed Central  Google Scholar 

  • Jiang HB, Xu M, Wang XP (2008) Pancreatic stellate cells promote proliferation and invasiveness of human pancreatic cancer cells via galectin-3. World J Gastroenterol 14(13):2023–2028

    CAS  PubMed  PubMed Central  Google Scholar 

  • Johnson KD et al (2007) Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia. Neoplasia 9(8):662–670

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kalousova M et al (2006) Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 47(3):406–411

    CAS  PubMed  Google Scholar 

  • Kanamori H et al (2007) Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun 360(4):772–777

    CAS  PubMed  Google Scholar 

  • Karachalias N et al (2003) Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem Soc Trans 31(Pt 6):1423–1425

    CAS  PubMed  Google Scholar 

  • Kawai T et al (2010) Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(varepsilon)-carboxymethyl lysine. J Diabetes Complications 24(6):424–432

    PubMed  Google Scholar 

  • Kellow NJ, Coughlan MT, Reid CM (2018) Association between habitual dietary and lifestyle behaviours and skin autofluorescence (SAF), a marker of tissue accumulation of advanced glycation endproducts (AGEs), in healthy adults. Eur J Nutr 57(6):2209–2216

    CAS  PubMed  Google Scholar 

  • Khalifah RG, Chen Y, Wassenberg JJ (2005) Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design. Ann N Y Acad Sci 1043:793–806

    CAS  PubMed  Google Scholar 

  • Kikuchi Y et al (2004) Galectin-3-positive cell infiltration in human diabetic nephropathy. Nephrol Dial Transplant 19(3):602–607

    CAS  PubMed  Google Scholar 

  • Kikuchi Y et al (2005) Advanced glycation end-product induces fractalkine gene upregulation in normal rat glomeruli. Nephrol Dial Transplant 20(12):2690–2696

    CAS  PubMed  Google Scholar 

  • Kilhovd BK et al (2003) Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism 52(2):163–167

    CAS  PubMed  Google Scholar 

  • Koulis C et al (2014) Role of bone-marrow- and non-bone-marrow-derived receptor for advanced glycation end-products (RAGE) in a mouse model of diabetes-associated atherosclerosis. Clin Sci (Lond) 127(7):485–497

    CAS  Google Scholar 

  • Koulis C et al (2015) Linking RAGE and Nox in diabetic micro- and macrovascular complications. Diabetes Metab 41(4):272–281

    CAS  PubMed  Google Scholar 

  • Kuniyasu A et al (2003) CD36-mediated endocytic uptake of advanced glycation end products (AGE) in mouse 3T3-L1 and human subcutaneous adipocytes. FEBS Lett 537(1–3):85–90

    CAS  PubMed  Google Scholar 

  • Lane TE, Fox HS, Buchmeier MJ (1999) Inhibition of nitric oxide synthase-2 reduces the severity of mouse hepatitis virus-induced demyelination: implications for NOS2/NO regulation of chemokine expression and inflammation. J Neurovirol 5(1):48–54

    CAS  PubMed  Google Scholar 

  • Lee FT et al (2004) Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol 15(8):2139–2151

    CAS  PubMed  Google Scholar 

  • Little WC et al (2005) The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 11(3):191–195

    CAS  PubMed  Google Scholar 

  • Liu SF, Ye X, Malik AB (1999a) Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents in vivo expression of proinflammatory genes. Circulation 100(12):1330–1337

    CAS  PubMed  Google Scholar 

  • Liu SF, Ye X, Malik AB (1999b) Pyrrolidine dithiocarbamate prevents I-kappaB degradation and reduces microvascular injury induced by lipopolysaccharide in multiple organs. Mol Pharmacol 55(4):658–667

    CAS  PubMed  Google Scholar 

  • Liu H et al (2005) Overexpression of AGE-receptor-1 (AGE-R1) in mice prevent AGE accumulation and delays diabetic renal injury. Diabetes 54(Suppl):A21-B

    Google Scholar 

  • Liu HQ et al (2006) Angiotensin II stimulates intercellular adhesion molecule-1 via an AT1 receptor/nuclear factor-kappaB pathway in brain microvascular endothelial cells. Life Sci 78(12):1293–1298

    CAS  PubMed  Google Scholar 

  • Liu YW et al (2017) Mangiferin upregulates glyoxalase 1 through activation of Nrf2/ARE signaling in central neurons cultured with high glucose. Mol Neurobiol 54(6):4060–4070

    CAS  PubMed  Google Scholar 

  • Lutgers HL et al (2006) Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 29(12):2654–2659

    PubMed  Google Scholar 

  • Maillard L (1912) Action des acides amines sur les sucres: formation des melanoidines par voie methodique. C R Acad Sci 154:66–68

    CAS  Google Scholar 

  • Makino H et al (2003) Roles of connective tissue growth factor and prostanoids in early streptozotocin-induced diabetic rat kidney: the effect of aspirin treatment. Clin Exp Nephrol 7(1):33–40

    CAS  PubMed  Google Scholar 

  • Makita Z et al (1991) Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325(12):836–842

    CAS  PubMed  Google Scholar 

  • Makita Z et al (1992) Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science 258(5082):651–653

    CAS  PubMed  Google Scholar 

  • Makita Z et al (1994) Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 343(8912):1519–1522

    CAS  PubMed  Google Scholar 

  • Malhotra A et al (1997) Experimental diabetes is associated with functional activation of protein kinase C epsilon and phosphorylation of troponin I in the heart, which are prevented by angiotensin II receptor blockade. Circ Res 81(6):1027–1033

    CAS  PubMed  Google Scholar 

  • Martin J et al (2005) Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta. Cardiovasc Res 65(3):694–701

    CAS  PubMed  Google Scholar 

  • Marx N et al (2004) Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 53(10):2662–2668

    CAS  PubMed  Google Scholar 

  • Massague J (1998) TGF-beta signal transduction. Annu Rev Biochem 67:753–791

    CAS  PubMed  Google Scholar 

  • Mastrocola R (2017) AGEs and neurodegeneration: the Nrf2/glyoxalase-1 interaction. Oncotarget 8(4):5645–5646

    PubMed  Google Scholar 

  • Matsui T et al (2007) Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation. J Int Med Res 35(4):482–489

    CAS  PubMed  Google Scholar 

  • Matsumoto R et al (1998) Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem 273(27):16976–16984

    CAS  PubMed  Google Scholar 

  • Mirmiranpour H et al (2013) Comparative effects of pioglitazone and metformin on oxidative stress markers in newly diagnosed type 2 diabetes patients: a randomized clinical trial. J Diabetes Complications 27(5):501–507

    PubMed  Google Scholar 

  • Miura J et al (2003) Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with type 1 diabetes. J Diabetes Complications 17(1):16–21

    PubMed  Google Scholar 

  • Miyata T et al (2000a) Mechanism of the inhibitory effect of OPB-9195 [(+/−)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide] on advanced glycation end product and advanced lipoxidation end product formation. J Am Soc Nephrol 11(9):1719–1725

    CAS  PubMed  Google Scholar 

  • Miyata T, Kurokawa K, Van Ypersele De Strihou C (2000b) Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J Am Soc Nephrol 11(9):1744–1752

    CAS  PubMed  Google Scholar 

  • Miyata T et al (2002) Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 13(10):2478–2487

    CAS  PubMed  Google Scholar 

  • Mizutani K et al (2002) Inhibitor for advanced glycation end products formation attenuates hypertension and oxidative damage in genetic hypertensive rats. J Hypertens 20(8):1607–1614

    CAS  PubMed  Google Scholar 

  • Monnier VM et al (1999) Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes control and complications trial. Diabetes 48(4):870–880

    CAS  PubMed  PubMed Central  Google Scholar 

  • Morcos M et al (2002) Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 51(12):3532–3544

    CAS  PubMed  Google Scholar 

  • Mulder DJ et al (2006) Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: an overview of current clinical studies, evidence, and limitations. Diabetes Technol Ther 8(5):523–535

    CAS  PubMed  Google Scholar 

  • Murphy M et al (1999) Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 274(9):5830–5834

    CAS  PubMed  Google Scholar 

  • Myint KM et al (2006) RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 55(9):2510–2522

    CAS  PubMed  Google Scholar 

  • Nakamura K et al (2005) Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res 70(3):137–141

    CAS  PubMed  Google Scholar 

  • Nakamura T et al (2010) Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs). Oxid Med Cell Longev 3(5):304–307

    PubMed  PubMed Central  Google Scholar 

  • Nangaku M et al (2003) Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 14(5):1212–1222

    CAS  PubMed  Google Scholar 

  • Nangia-Makker P et al (2007) Galectin-3 in apoptosis, a novel therapeutic target. J Bioenerg Biomembr 39(1):79–84

    CAS  PubMed  PubMed Central  Google Scholar 

  • Nathan DM et al (2003) Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 348(23):2294–2303

    PubMed  Google Scholar 

  • Neeper M et al (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267(21):14998–15004

    CAS  PubMed  Google Scholar 

  • Nicholson AC et al (2001) Role of CD36, the macrophage class B scavenger receptor, in atherosclerosis. Ann N Y Acad Sci 947:224–228

    CAS  PubMed  Google Scholar 

  • Nishikawa T et al (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404(6779):787–790

    CAS  PubMed  Google Scholar 

  • Odashima M et al (2006) Zinc L-carnosine protects colonic mucosal injury through induction of heat shock protein 72 and suppression of NF-kappaB activation. Life Sci 79(24):2245–2250

    CAS  PubMed  Google Scholar 

  • Ohgami N et al (2001a) CD36, a member of class B scavenger receptor family, is a receptor for advanced glycation end products. Ann N Y Acad Sci 947:350–355

    CAS  PubMed  Google Scholar 

  • Ohgami N et al (2001b) Scavenger receptor class B type I-mediated reverse cholesterol transport is inhibited by advanced glycation end products. J Biol Chem 276(16):13348–13355

    CAS  PubMed  Google Scholar 

  • Ohgami N et al (2003) Advanced glycation end products (AGE) inhibit scavenger receptor class B type I-mediated reverse cholesterol transport: a new crossroad of AGE to cholesterol metabolism. J Atheroscler Thromb 10(1):1–6

    CAS  PubMed  Google Scholar 

  • Ohsawa M et al (2015) Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia. Lipids Health Dis 14:161

    PubMed  PubMed Central  Google Scholar 

  • Ojima A et al (2015) Empagliflozin, an inhibitor of sodium-glucose Cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor Axis. Horm Metab Res 47(9):686–692

    CAS  PubMed  Google Scholar 

  • Ono Y et al (2013) Suppression of advanced glycation and lipoxidation end products by angiotensin II type-1 receptor blocker candesartan in type 2 diabetic patients with essential hypertension. Fukushima J Med Sci 59(2):69–75

    CAS  PubMed  Google Scholar 

  • Osicka TM et al (2000) Albuminuria in patients with type 1 diabetes is directly linked to changes in the lysosome-mediated degradation of albumin during renal passage. Diabetes 49(9):1579–1584

    CAS  PubMed  Google Scholar 

  • Penfold SA et al (2010) Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. Kidney Int 78(3):287–295

    CAS  PubMed  Google Scholar 

  • Pickering RJ et al (2019) Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis. J Clin Invest 129(1):406–421

    PubMed  Google Scholar 

  • Pieper GM, Riazulhaq (1997) Activation of nuclear factor-kappa-B in cultured endothelial cells by increased glucose concentration – prevention by Calphostin C. J Cardiovasc Pharmacol 30(4):528–532

    CAS  PubMed  Google Scholar 

  • Prevo R et al (2004) Rapid plasma membrane-endosomal trafficking of the lymph node sinus and high endothelial venule scavenger receptor/homing receptor stabilin-1 (FEEL-1/CLEVER-1). J Biol Chem 279(50):52580–52592

    CAS  PubMed  Google Scholar 

  • Prieto VG et al (2006) Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin Cancer Res 12(22):6709–6715

    CAS  PubMed  Google Scholar 

  • Rahbar S et al (2000) Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta 301(1–2):65–77

    CAS  PubMed  Google Scholar 

  • Rangan GK et al (1999) Inhibition of nuclear factor-kappa B activation reduces cortical tubulointerstitial injury in proteinuric rats. Kidney Int 56(1):118–134

    CAS  PubMed  Google Scholar 

  • Riser BL et al (2000) Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 11(1):25–38

    CAS  PubMed  Google Scholar 

  • Rizkalla B et al (2003) Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors. J Am Soc Nephrol 14(12):3061–3071

    CAS  PubMed  Google Scholar 

  • Rosca MG et al (2005) Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Renal Physiol 289(2):F420–F430

    CAS  PubMed  Google Scholar 

  • Schiel R et al (2003) Improvement in quality of diabetes control and concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus studied over a period of 10 years (JEVIN). J Diabetes Complications 17(2):90–97

    PubMed  Google Scholar 

  • Schiel R et al (2004) Improvement of the quality of diabetes control and decrease in the concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus: results from a 10 year-prospective, population-based survey on the quality of diabetes care in Germany (JEVIN). Eur J Med Res 9(8):391–399

    PubMed  Google Scholar 

  • Schlueter C et al (2003) Tissue-specific expression patterns of the RAGE receptor and its soluble forms – a result of regulated alternative splicing? Biochim Biophys Acta 1630(1):1–6

    CAS  PubMed  Google Scholar 

  • Schmidt AM et al (1994a) Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 14(10):1521–1528

    CAS  PubMed  Google Scholar 

  • Schmidt AM et al (1994b) The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. J Biol Chem 269(13):9882–9888

    CAS  PubMed  Google Scholar 

  • Schrijvers BF, De Vriese AS, Flyvbjerg A (2004) From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 25(6):971–1010

    CAS  PubMed  Google Scholar 

  • Sebekova K et al (2003) Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products. J Hum Hypertens 17(4):265–270

    CAS  PubMed  Google Scholar 

  • Sell DR et al (1992) Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes 41(10):1286–1292

    CAS  PubMed  Google Scholar 

  • Singh R et al (2001) Advanced glycation end-products: a review. Diabetologia 44(2):129–146

    CAS  PubMed  Google Scholar 

  • Son M et al (2017) Age dependent accumulation patterns of advanced glycation end product receptor (RAGE) ligands and binding intensities between RAGE and its ligands differ in the liver, kidney, and skeletal muscle. Immun Ageing 14:12

    PubMed  PubMed Central  Google Scholar 

  • Soro-Paavonen A et al (2008) Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 57(9):2461–2469

    CAS  PubMed  PubMed Central  Google Scholar 

  • Soulis T et al (1996) Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int 50(2):627–634

    CAS  PubMed  Google Scholar 

  • Soulis T et al (1997a) Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 40(6):619–628

    CAS  PubMed  Google Scholar 

  • Soulis T et al (1997b) Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats. Diabetologia 40(10):1141–1151

    CAS  PubMed  Google Scholar 

  • Soulis-Liparota T et al (1991) Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40(10):1328–1334

    CAS  PubMed  Google Scholar 

  • Soulis-Liparota T et al (1995) The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 38(4):387–394

    CAS  PubMed  Google Scholar 

  • Sourris KC, Forbes JM (2009) Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy – are these receptors valid therapeutic targets. Curr Drug Targets 10(1):42–50

    CAS  PubMed  Google Scholar 

  • Sourris KC et al (2010) Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor. Diabetologia 53(11):2442–2451

    CAS  PubMed  PubMed Central  Google Scholar 

  • Spadaccio C et al (2014) Simvastatin attenuates the endothelial pro-thrombotic shift in saphenous vein grafts induced by advanced glycation endproducts. Thromb Res 133(3):418–425

    CAS  PubMed  Google Scholar 

  • Steffes MW, Chavers BM, Molitch ME, Cleary PA, Lachin JM, Genuth S, Nathan DM (2003) Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the epidemiology of diabetes interventions and complications (EDIC) study. JAMA 290(16):2159–2167

    CAS  Google Scholar 

  • Stirban A et al (2006) Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 29(9):2064–2071

    CAS  PubMed  Google Scholar 

  • Stitt AW, He C, Vlassara H (1999) Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells. Biochem Biophys Res Commun 256(3):549–556

    CAS  PubMed  Google Scholar 

  • Stitt A et al (2002) The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51(9):2826–2832

    CAS  PubMed  Google Scholar 

  • Sugiyama S et al (1998) Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. J Am Soc Nephrol 9(9):1681–1688

    CAS  PubMed  Google Scholar 

  • Tamura Y et al (2003) FEEL-1 and FEEL-2 are endocytic receptors for advanced glycation end products. J Biol Chem 278(15):12613–12617

    CAS  PubMed  Google Scholar 

  • Tang L et al (2017) Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes. Am J Physiol Endocrinol Metab 313(5):E563–E576

    PubMed  Google Scholar 

  • Tesch GH (2008) MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 294(4):F697–F701

    CAS  PubMed  Google Scholar 

  • Thallas-Bonke V et al (2004) Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. Diabetes 53(11):2921–2930

    CAS  PubMed  Google Scholar 

  • Thallas-Bonke V et al (2014) Nox-4 deletion reduces oxidative stress and injury by PKC-alpha-associated mechanisms in diabetic nephropathy. Physiol Rep:2(11)

    Google Scholar 

  • Thomas MC (2011) Advanced glycation end products. Contrib Nephrol 170:66–74

    CAS  PubMed  Google Scholar 

  • Thomas MC et al (2005a) Low-molecular weight advanced glycation end products: markers of tissue AGE accumulation and more? Ann N Y Acad Sci 1043:644–654

    CAS  PubMed  Google Scholar 

  • Thomas MC et al (2005b) Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 16(10):2976–2984

    CAS  PubMed  Google Scholar 

  • Tikellis C et al (2014) Dicarbonyl stress in the absence of hyperglycemia increases endothelial inflammation and atherogenesis similar to that observed in diabetes. Diabetes 63(11):3915–3925

    CAS  PubMed  Google Scholar 

  • Tsuchida K et al (1999) Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 42(5):579–588

    CAS  PubMed  Google Scholar 

  • Twigg SM et al (2001) Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology 142(5):1760–1769

    CAS  PubMed  Google Scholar 

  • Twigg SM et al (2002a) Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 143(12):4907–4915

    CAS  PubMed  Google Scholar 

  • Twigg SM et al (2002b) Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 143(12):4907–4915

    CAS  PubMed  Google Scholar 

  • Uribarri J, Tuttle KR (2006) Advanced glycation end products and nephrotoxicity of high-protein diets. Clin J Am Soc Nephrol 1(6):1293–1299

    CAS  PubMed  Google Scholar 

  • Uribarri J et al (2003a) Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 14(3):728–731

    CAS  PubMed  Google Scholar 

  • Uribarri J et al (2003b) Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am J Kidney Dis 42(3):532–538

    CAS  PubMed  Google Scholar 

  • Urios P, Grigorova-Borsos AM, Sternberg M (2007) Aspirin inhibits the formation of pentosidine, a cross-linking advanced glycation end product, in collagen. Diabetes Res Clin Pract 77(2):337–340

    CAS  PubMed  Google Scholar 

  • Vasan S et al (1996) An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382:275–278

    CAS  PubMed  Google Scholar 

  • Vlad A et al (2017) Therapy with atorvastatin versus rosuvastatin reduces urinary podocytes, podocyte-associated molecules, and proximal tubule dysfunction biomarkers in patients with type 2 diabetes mellitus: a pilot study. Ren Fail 39(1):112–119

    CAS  PubMed  Google Scholar 

  • Vlassara H (1995) Advanced glycation in diabetic renal and vascular disease. Kidney Int Suppl 51:S43–S44

    CAS  PubMed  Google Scholar 

  • Vlassara H (1997) Recent progress in advanced glycation end products and diabetic complications. Diabetes 46(Suppl 2):S19–S25

    CAS  PubMed  Google Scholar 

  • Vlassara H (2001) The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 17(6):436–443

    CAS  PubMed  Google Scholar 

  • Vlassara H, Bucala R (1996) Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Diabetes 45(Suppl 3):S65–S66

    CAS  PubMed  Google Scholar 

  • Wada R, Yagihashi S (2005) Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Ann N Y Acad Sci 1043:598–604

    CAS  PubMed  Google Scholar 

  • Wada R et al (2001) Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy. Eur J Clin Invest 31(6):513–520

    CAS  PubMed  Google Scholar 

  • Wang B et al (2014) Transforming growth factor-beta1-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b. Kidney Int 85(2):352–361

    CAS  PubMed  Google Scholar 

  • Waris S et al (2015) Increased DNA dicarbonyl glycation and oxidation markers in patients with type 2 diabetes and link to diabetic nephropathy. J Diabetes Res 2015:915486

    PubMed  PubMed Central  Google Scholar 

  • Watson A, Thomas M, Koh P, Figarola J, Rahbar S, Jandeleit-Dahm K (2010) Attenuation of diabetes associated atherosclerosis with LR-90, a novel inhibitor of AGE formation. J R Soc Chem:137–143

    Google Scholar 

  • Watson AM et al (2011) Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia 54(3):681–689

    CAS  PubMed  Google Scholar 

  • Watson AM et al (2012) Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice. Diabetes 61(8):2105–2113

    CAS  PubMed  PubMed Central  Google Scholar 

  • Watson AM et al (2014) Quinapril treatment abolishes diabetes-associated atherosclerosis in RAGE/apolipoprotein E double knockout mice. Atherosclerosis 235(2):444–448

    CAS  PubMed  Google Scholar 

  • Wautier JL, Guillausseau PJ (2001) Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 27(5 Pt 1):535–542

    CAS  PubMed  Google Scholar 

  • Wautier JL et al (1996) Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 97(1):238–243

    CAS  PubMed  PubMed Central  Google Scholar 

  • Wautier MP et al (2003) N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients. Diabetes Metab 29(1):44–52

    CAS  PubMed  Google Scholar 

  • Wendt T et al (2003a) Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 14(5):1383–1395

    CAS  PubMed  Google Scholar 

  • Wendt TM et al (2003b) RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162(4):1123–1137

    CAS  PubMed  PubMed Central  Google Scholar 

  • Williams ME et al (2007) Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 27(6):605–614

    CAS  PubMed  Google Scholar 

  • Wortmann M et al (2016) A Glyoxalase-1 knockdown does not have major short term effects on energy expenditure and atherosclerosis in mice. J Diabetes Res 2016:2981639

    PubMed  Google Scholar 

  • Xia P et al (1994) Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 43(9):1122–1129

    CAS  PubMed  Google Scholar 

  • Xue M et al (2016) Improved glycemic control and vascular function in overweight and obese subjects by glyoxalase 1 inducer formulation. Diabetes 65(8):2282–2294

    CAS  PubMed  Google Scholar 

  • Yamamoto Y et al (2001) Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108(2):261–268

    CAS  PubMed  PubMed Central  Google Scholar 

  • Yan SD et al (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269(13):9889–9897

    CAS  PubMed  Google Scholar 

  • Yan SD, Stern D, Schmidt AM (1997) What's the RAGE? The receptor for advanced glycation end products (RAGE) and the dark side of glucose. Eur J Clin Invest 27(3):179–181

    CAS  PubMed  Google Scholar 

  • Yan SF et al (2006) Receptor for advanced glycation end products and the cardiovascular complications of diabetes and beyond: lessons from AGEing. Endocrinol Metab Clin North Am 35(3):511–524. viii

    CAS  PubMed  Google Scholar 

  • Yang Z et al (1991) Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins. J Exp Med 174(3):515–524

    CAS  PubMed  Google Scholar 

  • Yang CW et al (1994) Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci U S A 91(20):9436–9440

    CAS  PubMed  PubMed Central  Google Scholar 

  • Yonemura S, Tsukita S (1999) Direct involvement of ezrin/radixin/moesin (ERM)-binding membrane proteins in the organization of microvilli in collaboration with activated ERM proteins. J Cell Biol 145(7):1497–1509

    CAS  PubMed  PubMed Central  Google Scholar 

  • Younis NN et al (2010) Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes. Diab Vasc Dis Res 7(4):289–295

    PubMed  Google Scholar 

  • Zhang Z et al (2008) Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci U S A 105(41):15896–15901

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zheng F, Guan Y (2007) Thiazolidinediones: a novel class of drugs for the prevention of diabetic nephropathy? Kidney Int 72(11):1301–1303

    CAS  PubMed  Google Scholar 

  • Zheng F et al (2006) Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. Kidney Int 70(3):507–514

    CAS  PubMed  Google Scholar 

  • Zhuang A et al (2017) Increased liver AGEs induce hepatic injury mediated through an OST48 pathway. Sci Rep 7(1):12292

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, Australia

    Karly C. Sourris, Anna Watson & Karin Jandeleit-Dahm

Authors
  1. Karly C. Sourris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Watson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karin Jandeleit-Dahm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karin Jandeleit-Dahm .

Editor information

Editors and Affiliations

  1. Department of Pharmacology and Personalised Medicine, Maastricht University, Maastricht, The Netherlands

    Harald H. H. W. Schmidt

  2. Brighton and Sussex Medical School, Brighton, UK

    Pietro Ghezzi

  3. Department of Biochemistry, Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain

    Antonio Cuadrado

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sourris, K.C., Watson, A., Jandeleit-Dahm, K. (2020). Inhibitors of Advanced Glycation End Product (AGE) Formation and Accumulation. In: Schmidt, H.H.H.W., Ghezzi, P., Cuadrado, A. (eds) Reactive Oxygen Species . Handbook of Experimental Pharmacology, vol 264. Springer, Cham. https://doi.org/10.1007/164_2020_391

Download citation

Publish with us

Policies and ethics